GANX241220C4000
- 0.00
- 0.000.00%
Gain Therapeutics Newsroom
Promising Preclinical Data and Financial Position Support Buy Rating for Gain Therapeutics
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5
Chardan Capital Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $6
Gain Therapeutics Advances Parkinson's Therapy Development
Gain Therapeutics Receives Buy Rating as GT-02287 Shows Promise for GBA1 Parkinson's Disease
Gain Therapeutics | 8-K: Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Gain Therapeutics Reports Q3 EPS (17c), Consensus (21c)
Express News | Gain Therapeutics Q3 2024 GAAP EPS $(0.17) Beats $(0.21) Estimate
Gain Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Gain Therapeutics Shares Are Trading Higher After the Company Announced He Presentation of a Poster That Details the Use of Its Magellan Drug Discovery Platform to Identify Allosteric Inhibitors Targeting Discoidin Domain Receptor 2.
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference
Gain Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Gain Therapeutics Excels in Neurodegenerative Drug Trials
Gain Therapeutics Presents Preclinical Data on GT-02287
Express News | Gain Therapeutics Announced The Presentation Of New Evidence Supporting The Disease-modifying Activity Of Gt-02287 In Preclinical Animal Models Of Both GBA-1 And Idiopathic Parkinson's Disease
Gain Therapeutics to Participate at Upcoming Investor Conferences
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8